This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Rett syndrome (RS)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Rett syndrome is a sporadic pervasive developmental disorder which is observed almost exclusively in females (see notes at end of page)

The prognosis is poor, with symptomatic relief being the only treatment option.

Rett syndrome (RS) is a neurodevelopmental syndrome affecting almost exclusively female children and first appearing at 7–18 months

  • prior to the onset of symptoms, development appears normal (1,2)
  • after symptomatic onset patient development deteriorates rapidly and severe dementia, autism and other features develop
  • the locus for inheritance of this condition is Xq28
    • RS results from mutations in the in the methyl-CpG-binding protein-2 gene (MECP2)
    • inherited as an X-linked dominant
    • most cases are sporadic; de novo mutations occur almost exclusively on the paternally derived X chromosome
    • prevalence 1 in 10,000 to 1 in 15,000 female births
  • is not a neurodegenerative condition, rather it is a progressive disorder involving multisystem symptom evolution over time (3)
  • 70% of patients with RS live to at least 50 years of age (3)

  • features associated with RS include:
    • short stature
    • cachexia
    • head circumference is normal at birth but thereis deceleration of head growth
      • growth of the head decelerates between six months and four years and consequent microcephaly
    • bruxism of the teeth
    • cardiological features include prolonged QTc interval and T-wave abnormalities
    • respiratory features include
      • periodic apnoea whilst awake
      • breath holding
      • intermittent hyperventilation
    • abdominal features include
      • constipation
      • gastroesophageal reflux
    • skeletal abnormalities include scoliosis; kyphosis
    • patients have small and cold feet
    • neurological features
      • development is normal until until 6-18 months
      • subsequent development of mental retardation, spasticity
      • seizures develop in up to 75%
    • behavioral/psychiatric manifestations include
      • autistic behaviors
      • hand stereotypies - often clasped together, with wringing movements and clapping
      • sleep disturbance
      • bruxism
      • breath holding

Notes:

* there have been rare reports of Rett syndrome in males

  • four male patients in the same family have Rett syndrome with severe mental retardation (4)
  • two males in a second family had progressive spasticity (5)

Reference:

  1. Ausio J et al. Syndromes of Chromatin remodeling. Clinical Genetics 2003; 64(2):83-95
  2. Percy A et al "Rett syndrome and the autistic disorders". Neurol. Clin. 1990, 8(3), p.659-76
  3. Fu C, Armstrong D, Marsh E, Lieberman D, Motil K, Witt R, Standridge S, Nues P, Lane J, Dinkel T, Coenraads M, von Hehn J, Jones M, Hale K, Suter B, Glaze D, Neul J, Percy A, Benke T. Consensus guidelines on managing Rett syndrome across the lifespan. BMJ Paediatr Open. 2020 Sep 13;4(1):e000717. doi: 10.1136/bmjpo-2020-000717. PMID: 32984552; PMCID: PMC7488790.
  4. Orrico A, Lam C, Galli L et al. MECP2 mutation in male patients with non-specific X-linked mental retardation . FEBS Lett 2000: 481 (3): 285 288.
  5. Meloni I, Bruttini M, Longo I et al. A mutation in the Rett syndrome gene, MECP2, causes X-linked mental retardation and progressive spasticity in males . Am J Hum Genet 2000: 67: 982 985.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.